Condition: Breast Cancer · Estrogen Receptor Positive Tumor · HER2-negative Breast Cancer · Sponsor: Gangnam Severance Hospital
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
This description comes directly from the study's public registry record.
Sung Gwe Ahn, M.D.,Ph.D. · 0220193370 · asg2004@yuhs.ac
Always discuss trial participation with your own doctor first.
| Gangnam Severance Hospital | Seoul, Korea, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05333328